{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:28:18Z","timestamp":1762338498431,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013003","name":"Universit\u00e0 degli Studi di Cagliari","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Little is known about vaccine safety in inborn errors of immunity (IEI) patients during the current vaccination campaign for COVID-19. To better investigate the reactogenicity and adverse event profile after two, three, and four doses of mRNA vaccines, we conducted an observational, multicentric study on 342 PID patients from four Italian Referral Centres.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a survey on self-reported adverse reactions in IEI patients who received mRNA vaccine by administering a questionnaire after each dose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Over the whole study period, none of the patients needed hospitalization or had hypersensitivity reactions, including anaphylaxis and delayed injection site reaction. After two vaccination doses, 35.4% of patients showed only local reactogenicity-related symptoms (RrS), 44.4% reported both systemic and local RrS, and 5% reported only systemic RrS. In more than 60% of cases, local or systemic RrS were mild. After the first and second booster doses, patients showed fewer adverse events (AEs) than after the first vaccination course. Patients aged 50\u00a0years and older reported adverse events and RrS less frequently. Among AEs requiring treatment, one common variable immune deficiency patient affected by T cell large granular lymphocytic leukemia developed neutropenia and one patient had Bell\u2019s paralysis perhaps during herpes zoster reactivation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although our follow-up period is relatively short, the safety data we reported are reassuring. This data would help to contrast the vaccine hesitancy often manifested by patients with IEI and to better inform their healthcare providers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10875-022-01402-6","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T14:04:42Z","timestamp":1668434682000},"page":"299-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety of mRNA COVID-19 Vaccines in Patients with Inborn Errors of Immunity: an Italian Multicentric Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Cinzia","family":"Milito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cinetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Garzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Puca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"De Vitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Punziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Lagnese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Del Giacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Quinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5768-391X","authenticated-orcid":false,"given":"Davide","family":"Firinu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"issue":"3","key":"1402_CR1","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"CC Lai","year":"2020","unstructured":"Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105924.","journal-title":"Int J Antimicrob Agents"},{"key":"1402_CR2","unstructured":"World Health Organization.\u00a02022. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports. Accessed 08\/21\/2022."},{"key":"1402_CR3","unstructured":"Modifica della determina n. 1285\/2021 concernente l\u2019utilizzo dose addizionale dei medicinali \u00abBNT162b2\u00bb e \u00abmRNA1273\u00bb. (Determina DG n. 1352). Gazzetta Ufficiale Serie Generale. 2021;279."},{"key":"1402_CR4","unstructured":"Ministero della Salute. Vaccini anti-COVID-19. https:\/\/www.salute.gov.it\/informazione\/vaccino."},{"key":"1402_CR5","doi-asserted-by":"publisher","first-page":"727850","DOI":"10.3389\/fimmu.2021.727850","volume":"12","author":"D Amodio","year":"2021","unstructured":"Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, et al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. Front Immunol. 2021;12:727850. https:\/\/doi.org\/10.3389\/fimmu.2021.727850.","journal-title":"Front Immunol"},{"issue":"9","key":"1402_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/biomedicines9091163","volume":"9","author":"R D\u2019Amelio","year":"2021","unstructured":"D\u2019Amelio R, Asero R, Cassatella MA, Lagan\u00e0 B, Lunardi C, Migliorini P, et al. Anti-COVID-19 vaccination in patients with autoimmune-autoinflammatory disorders and primary\/secondary immunodeficiencies: the position of the task force on behalf of the Italian Immunological Societies. Biomedicines. 2021;9(9):1163.","journal-title":"Biomedicines"},{"key":"1402_CR7","doi-asserted-by":"publisher","first-page":"895209","DOI":"10.3389\/fimmu.2022.895209","volume":"13","author":"A Antoli","year":"2022","unstructured":"Antoli A, Rocamora-Blanch G, Framil M, Mas-Bosch V, Navarro S, Bermudez C, et al. Evaluation of humoral and cellular immune responses to the SARS-CoV-2 vaccine in patients with common variable immunodeficiency phenotype and patient receiving B-cell depletion therapy. Front Immunol. 2022;13:895209. https:\/\/doi.org\/10.3389\/fimmu.2022.895209.","journal-title":"Front Immunol"},{"issue":"2","key":"1402_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10875-021-01174-5","volume":"42","author":"D Arroyo-Sanchez","year":"2022","unstructured":"Arroyo-Sanchez D, Cabrera-Marante O, Laguna-Goya R, Almendro-Vazquez P, Carretero O, Gil-Etayo FJ, et al. Immunogenicity of anti-SARS-CoV-2 vaccines in common variable immunodeficiency. J Clin Immunol. 2022;42(2):240\u201352. https:\/\/doi.org\/10.1007\/s10875-021-01174-5.","journal-title":"J Clin Immunol"},{"key":"1402_CR9","doi-asserted-by":"publisher","first-page":"815404","DOI":"10.3389\/fimmu.2021.815404","volume":"12","author":"I Quinti","year":"2021","unstructured":"Quinti I, Locatelli F, Carsetti R. The immune response to SARS-CoV-2 vaccination: insights learned from adult patients with common variable immune deficiency. Front Immunol. 2021;12:815404. https:\/\/doi.org\/10.3389\/fimmu.2021.815404.","journal-title":"Front Immunol"},{"key":"1402_CR10","doi-asserted-by":"publisher","unstructured":"Pulvirenti F, Fernandez Salinas A, Milito C, Terreri S, Piano Mortari E, Quintarelli C et al. B cell response induced by SARS-CoV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies. Cells. 2021;10(11). https:\/\/doi.org\/10.3390\/cells10112915.","DOI":"10.3390\/cells10112915"},{"key":"1402_CR11","doi-asserted-by":"publisher","unstructured":"Pham MN, Murugesan K, Banaei N, Pinsky BA, Tang M, Hoyte E et al. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. J Allergy Clin Immunol. 2022;149(3):907\u201311 e3. https:\/\/doi.org\/10.1016\/j.jaci.2021.11.022","DOI":"10.1016\/j.jaci.2021.11.022"},{"issue":"8","key":"1402_CR12","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s10875-021-01133-0","volume":"41","author":"AF Salinas","year":"2021","unstructured":"Salinas AF, Mortari EP, Terreri S, Quintarelli C, Pulvirenti F, Di Cecca S, et al. SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best. J Clin Immunol. 2021;41(8):1709\u201322. https:\/\/doi.org\/10.1007\/s10875-021-01133-0.","journal-title":"J Clin Immunol"},{"issue":"767","key":"1402_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.53738\/REVMED.2022.18.767.190","volume":"18","author":"V Favre","year":"2022","unstructured":"Favre V, Ekobena P, Chtioui H, Rothuizen LE, Livio F, Genton B, et al. Pharmacovigilance - mRNA COVID-19 vaccines\u202f: current state of knowledge on their adverse effects. Rev Med Suisse. 2022;18(767):190\u20137. https:\/\/doi.org\/10.53738\/REVMED.2022.18.767.190.","journal-title":"Rev Med Suisse"},{"issue":"7","key":"1402_CR14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939\u201349. https:\/\/doi.org\/10.1016\/S1473-3099(21)00224-3.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"1402_CR15","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.jaci.2022.04.002","volume":"149","author":"LPM van Leeuwen","year":"2022","unstructured":"van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, et al. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. J Allergy Clin Immunol. 2022;149(6):1949\u201357. https:\/\/doi.org\/10.1016\/j.jaci.2022.04.002.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1402_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13223-022-00679-x","volume":"18","author":"B Aberumand","year":"2022","unstructured":"Aberumand B, Ayoub Goulstone W, Betschel S. Understanding attitudes and obstacles to vaccination against COVID-19 in patients with primary immunodeficiency. Allergy Asthma Clin Immunol. 2022;18(1):38. https:\/\/doi.org\/10.1186\/s13223-022-00679-x.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"7","key":"1402_CR17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10875-020-00844-0","volume":"40","author":"V Lougaris","year":"2020","unstructured":"Lougaris V, Pession A, Baronio M, Soresina A, Rondelli R, Gazzurelli L, et al. The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): twenty years of experience (1999\u20132019). J Clin Immunol. 2020;40(7):1026\u201337. https:\/\/doi.org\/10.1007\/s10875-020-00844-0.","journal-title":"J Clin Immunol"},{"key":"1402_CR18","doi-asserted-by":"publisher","first-page":"103705","DOI":"10.1016\/j.ebiom.2021.103705","volume":"74","author":"P Bergman","year":"2021","unstructured":"Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine. 2021;74:103705. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103705.","journal-title":"EBioMedicine"},{"issue":"27","key":"1402_CR19","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2034577.","journal-title":"N Engl J Med"},{"issue":"2","key":"1402_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jsps.2021.12.008","volume":"30","author":"OM Albalawi","year":"2022","unstructured":"Albalawi OM, Alomran MI, Alsagri GM, Althunian TA, Alshammari TM. Analyzing the U.S. post-marketing safety surveillance of COVID-19 vaccines. Saudi Pharm J. 2022;30(2):180\u20134. https:\/\/doi.org\/10.1016\/j.jsps.2021.12.008.","journal-title":"Saudi Pharm J"},{"key":"1402_CR21","doi-asserted-by":"publisher","first-page":"876336","DOI":"10.3389\/fpubh.2022.876336","volume":"10","author":"S Ganesan","year":"2022","unstructured":"Ganesan S, Al Ketbi LMB, Al Kaabi N, Al Mansoori M, Al Maskari NN, Al Shamsi MS, et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE-an observational study. Front Public Health. 2022;10:876336. https:\/\/doi.org\/10.3389\/fpubh.2022.876336.","journal-title":"Front Public Health"},{"issue":"4","key":"1402_CR22","doi-asserted-by":"publisher","first-page":"e227657","DOI":"10.1001\/jamanetworkopen.2022.7657","volume":"5","author":"O Auster","year":"2022","unstructured":"Auster O, Finkel U, Dagan N, Barda N, Laufer A, Balicer RD, et al. Short-term adverse events after the third dose of the BNT162b2 mRNA COVID-19 vaccine in adults 60 years or older. JAMA Netw Open. 2022;5(4):e227657. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.7657.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1402_CR23","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","volume":"22","author":"C Menni","year":"2022","unstructured":"Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022;22(7):1002\u201310. https:\/\/doi.org\/10.1016\/S1473-3099(22)00146-3.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1402_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"APS Munro","year":"2022","unstructured":"Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131\u201341. https:\/\/doi.org\/10.1016\/S1473-3099(22)00271-7.","journal-title":"Lancet Infect Dis"},{"key":"1402_CR25","doi-asserted-by":"publisher","unstructured":"Durkee-Shock JR, Keller MD. Immunizing the imperfect immune system: coronavirus disease 2019 vaccination in patients with inborn errors of immunity. Ann Allergy Asthma Immunol. 2022.\u00a0129(5):562\u201371 e1.\u00a0https:\/\/doi.org\/10.1016\/j.anai.2022.06.009.","DOI":"10.1016\/j.anai.2022.06.009"},{"issue":"4","key":"1402_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.anai.2021.07.026","volume":"127","author":"C Romano","year":"2021","unstructured":"Romano C, Esposito S, Donnarumma G, Marrone A. Detection of neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines. Ann Allergy Asthma Immunol. 2021;127(4):499\u2013501. https:\/\/doi.org\/10.1016\/j.anai.2021.07.026.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1402_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","journal-title":"N Engl J Med"},{"issue":"6","key":"1402_CR28","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1152\/physiol.00016.2022","volume":"37","author":"OM Delmonte","year":"2022","unstructured":"Delmonte OM, Castagnoli R, Notarangelo LD. COVID-19 and inborn errors of immunity. Physiology (Bethesda). 2022;37(6):0. https:\/\/doi.org\/10.1152\/physiol.00016.2022.","journal-title":"Physiology (Bethesda)"},{"key":"1402_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.07.005","author":"Y Gao","year":"2022","unstructured":"Gao Y, Cai C, Wullimann D, Niessl J, Rivera-Ballesteros O, Chen P, et al. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity. 2022. https:\/\/doi.org\/10.1016\/j.immuni.2022.07.005.","journal-title":"Immunity"},{"key":"1402_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01231-7","author":"AM Shields","year":"2022","unstructured":"Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, et al. SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD Study. J Clin Immunol. 2022. https:\/\/doi.org\/10.1007\/s10875-022-01231-7.","journal-title":"J Clin Immunol"},{"key":"1402_CR31","doi-asserted-by":"publisher","first-page":"907125","DOI":"10.3389\/fimmu.2022.907125","volume":"13","author":"V Goda","year":"2022","unstructured":"Goda V, Krivan G, Kulcsar A, Gonczi M, Tasnady S, Matula Z, et al. Specific antibody and the T-cell response elicited by BNT162b2 boosting after two ChAdOx1 nCoV-19 in common variable immunodeficiency. Front Immunol. 2022;13:907125. https:\/\/doi.org\/10.3389\/fimmu.2022.907125.","journal-title":"Front Immunol"},{"key":"1402_CR32","doi-asserted-by":"publisher","unstructured":"Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life (Basel). 2021;11(3). https:\/\/doi.org\/10.3390\/life11030249.","DOI":"10.3390\/life11030249"},{"issue":"7844","key":"1402_CR33","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1038\/s41586-020-03098-3","volume":"590","author":"MJ Mulligan","year":"2021","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Publisher correction: Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2021;590(7844):E26. https:\/\/doi.org\/10.1038\/s41586-020-03098-3.","journal-title":"Nature"},{"issue":"4","key":"1402_CR34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ajh.26478","volume":"97","author":"CW Sing","year":"2022","unstructured":"Sing CW, Tang CTL, Chui CSL, Fan M, Lai FTT, Li X, et al. COVID-19 vaccines and risks of hematological abnormalities: nested case-control and self-controlled case series study. Am J Hematol. 2022;97(4):470\u201380. https:\/\/doi.org\/10.1002\/ajh.26478.","journal-title":"Am J Hematol"},{"key":"1402_CR35","doi-asserted-by":"publisher","unstructured":"Loosen SH, Bohlken J, Weber K, Konrad M, Luedde T, Roderburg C et al. Factors associated with non-severe adverse reactions after vaccination against SARS-CoV-2: a cohort study of 908,869 outpatient vaccinations in Germany. Vaccines (Basel). 2022;10(4). https:\/\/doi.org\/10.3390\/vaccines10040566.","DOI":"10.3390\/vaccines10040566"},{"issue":"2","key":"1402_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.6004\/jnccn.2021.7113","volume":"20","author":"RM Shulman","year":"2022","unstructured":"Shulman RM, Weinberg DS, Ross EA, Ruth K, Rall GF, Olszanski AJ, et al. Adverse events reported by patients with cancer after administration of a 2-dose mRNA COVID-19 vaccine. J Natl Compr Canc Netw. 2022;20(2):160\u20136. https:\/\/doi.org\/10.6004\/jnccn.2021.7113.","journal-title":"J Natl Compr Canc Netw"},{"key":"1402_CR37","doi-asserted-by":"publisher","unstructured":"Firinu D, Perra A, Campagna M, Littera R, Fenu G, Meloni F et al. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clin Exp Med. 2022; 22(3):477\u201385. https:\/\/doi.org\/10.1007\/s10238-021-00771-3.","DOI":"10.1007\/s10238-021-00771-3"},{"issue":"27","key":"1402_CR38","doi-asserted-by":"publisher","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","volume":"70","author":"JW Gargano","year":"2021","unstructured":"Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977\u201382. https:\/\/doi.org\/10.15585\/mmwr.mm7027e2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"1402_CR39","doi-asserted-by":"publisher","first-page":"e060425","DOI":"10.1136\/bmjopen-2021-060425","volume":"12","author":"S Lane","year":"2022","unstructured":"Lane S, Yeomans A, Shakir S. Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. BMJ Open. 2022;12(7):e060425. https:\/\/doi.org\/10.1136\/bmjopen-2021-060425.","journal-title":"BMJ Open"},{"issue":"6","key":"1402_CR40","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","volume":"144","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144(6):471\u201384. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056135.","journal-title":"Circulation"},{"issue":"1","key":"1402_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10875-016-0353-7","volume":"37","author":"H Hartman","year":"2017","unstructured":"Hartman H, Schneider K, Hintermeyer M, Bausch-Jurken M, Fuleihan R, Sullivan KE, et al. Lack of clinical hypersensitivity to penicillin antibiotics in common variable immunodeficiency. J Clin Immunol. 2017;37(1):22\u20134. https:\/\/doi.org\/10.1007\/s10875-016-0353-7.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1402_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1473-3099(21)00451-5","volume":"22","author":"EYF Wan","year":"2022","unstructured":"Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, et al. Bell\u2019s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2022;22(1):64\u201372. https:\/\/doi.org\/10.1016\/S1473-3099(21)00451-5.","journal-title":"Lancet Infect Dis"},{"key":"1402_CR43","doi-asserted-by":"publisher","unstructured":"Hoste L, researchers M-C, Soriano-Arandes A, Buddingh EP, Whittaker E, Belot A et al. Severe acute respiratory syndrome coronavirus 2 vaccination in children with a history of multisystem inflammatory syndrome in children: an international survey. J Pediatr. 2022;248:114\u20138. https:\/\/doi.org\/10.1016\/j.jpeds.2022.05.028.","DOI":"10.1016\/j.jpeds.2022.05.028"},{"issue":"8","key":"1402_CR44","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1111\/jdv.18184","volume":"36","author":"M Hertel","year":"2022","unstructured":"Hertel M, Heiland M, Nahles S, von Laffert M, Mura C, Bourne PE, et al. Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus. J Eur Acad Dermatol Venereol. 2022;36(8):1342\u20138. https:\/\/doi.org\/10.1111\/jdv.18184.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1402_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.11.025","author":"M Birabaharan","year":"2021","unstructured":"Birabaharan M, Kaelber DC, Karris MY. Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: a cohort study. J Am Acad Dermatol. 2021. https:\/\/doi.org\/10.1016\/j.jaad.2021.11.025.","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"1402_CR46","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood.2022015470","volume":"139","author":"G Moulis","year":"2022","unstructured":"Moulis G, Crickx E, Thomas L, Massy N, Mahevas M, Valnet-Rabier MB, et al. De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring. Blood. 2022;139(16):2561\u20135. https:\/\/doi.org\/10.1182\/blood.2022015470.","journal-title":"Blood"},{"issue":"1","key":"1402_CR47","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1038\/s41467-022-32264-6","volume":"13","author":"CR Simpson","year":"2022","unstructured":"Simpson CR, Kerr S, Katikireddi SV, McCowan C, Ritchie LD, Pan J, et al. Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Commun. 2022;13(1):4800. https:\/\/doi.org\/10.1038\/s41467-022-32264-6.","journal-title":"Nat Commun"},{"key":"1402_CR48","doi-asserted-by":"publisher","first-page":"n1931","DOI":"10.1136\/bmj.n1931","volume":"374","author":"J Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374:n1931. https:\/\/doi.org\/10.1136\/bmj.n1931.","journal-title":"BMJ"},{"issue":"1","key":"1402_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s10875-017-0456-9","volume":"38","author":"EJ Feuille","year":"2018","unstructured":"Feuille EJ, Anooshiravani N, Sullivan KE, Fuleihan RL, Cunningham-Rundles C. Autoimmune cytopenias and associated conditions in CVID: a report from the USIDNET Registry. J Clin Immunol. 2018;38(1):28\u201334. https:\/\/doi.org\/10.1007\/s10875-017-0456-9.","journal-title":"J Clin Immunol"},{"key":"1402_CR50","doi-asserted-by":"publisher","first-page":"947174","DOI":"10.3389\/fimmu.2022.947174","volume":"13","author":"G Garzi","year":"2022","unstructured":"Garzi G, Cinetto F, Firinu D, Di Napoli G, Lagnese G, Punziano A, et al. Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic. Front Immunol. 2022;13:947174. https:\/\/doi.org\/10.3389\/fimmu.2022.947174.","journal-title":"Front Immunol"},{"issue":"7","key":"1402_CR51","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s10875-021-01101-8","volume":"41","author":"JD Squire","year":"2021","unstructured":"Squire JD, Joshi AY. Safety of COVID-19 vaccination in immune-deficient patients receiving supplemental immunoglobulin therapies. J Clin Immunol. 2021;41(7):1527\u201330. https:\/\/doi.org\/10.1007\/s10875-021-01101-8.","journal-title":"J Clin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01402-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-022-01402-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-022-01402-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T14:44:07Z","timestamp":1675262647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-022-01402-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1007\/s10875-022-01402-6","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"type":"print","value":"0271-9142"},{"type":"electronic","value":"1573-2592"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"23 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Ethical Committee of the Sapienza University of Rome (CE 5834, n.052\/2020 and CE 4604, n.316\/2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was waived by the Institutional Review Board due to the observational nature of the study and anonymization before analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}